Recent genome-wide association studies (GWAS) have revealed genetic risk factors in autoimmune and inflammatory disorders. Several of the associated genes and underlying pathways are shared by various autoimmune diseases. Rheumatoid arthritis (RA) and coeliac disease (CD) are two autoimmune disorders which have commonalities in their pathogenesis. We aimed to replicate known RA loci in a Dutch RA population, and to investigate whether the effect of known RA and CD risk factors generalize across the two diseases. We selected all loci associated to either RA or CD in a GWAS and confirmed in an independent cohort, with a combined P-value cut-off P < 5 3 10
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disorder affecting 1% of the adult population. The disease is characterized by inflammation of the synovial tissue of multiple joints leading to pain, deformities and a reduced quality of life. The aetiology of RA is complex and largely unknown; however, epidemiologic data support a polygenic susceptibility model (1) . Besides this, environmental factors may also play a role in the pathogenesis of RA (2) .
RA shares common pathogenic mechanisms with other autoimmune disorders. This is reflected by the co-occurrence of several autoimmune disorders in some patients and families, and the shared genetic background of autoimmune diseases (3, 4) . One of the autoimmune disorders showing similar pathogenic mechanisms to those seen in RA is coeliac disease (CD). This is a chronic intestinal inflammatory disorder which develops through an intolerance to gluten-the major dietary protein in wheat-, and related proteins from barley and rye (5) . Although the diseases are clearly distinct in their phenotype, common features in RA and CD include the association of the HLA molecules with the diseases, T-cell infiltration in the target organs, the development of disease-specific auto-antibodies and the role of enzymes involved in post-translational modifications in the pathogenesis of the diseases (6) . In addition, several studies show co-occurrence of CD and RA (7 -10) . However, there are no well-designed studies to assess the true prevalence of RA and CD co-morbidity.
Recently performed genome-wide association studies (GWAS) have identified 11 loci associated with RA and 10 loci associated with CD, in addition to the already known HLA loci (11 -21) (Supplementary Material, Table S1 ). These GWAS showed that, besides HLA, two chromosomal regions are shared between RA and CD: a region on chromosome 4q27 (including the genes IL2 and IL21) and the 6q23.3 locus containing the OLIG3 and TNFAIP3 genes (22) . Interestingly, the IL2/IL21 locus has also been associated with psoriatic arthritis, Grave's disease and type 1 diabetes, whereas the OLIG3/TNFAIP3 locus has also been associated to systemic lupus erythematosus and type 1 diabetes (13,23 -27) . These results strongly suggest that overlapping genetic mechanisms underlie the development of multiple autoimmune disorders (4) . We therefore hypothesize that other susceptibility genes identified for RA might also contribute to the development of CD and vice versa. In this study, we investigated a total of 22 SNPs associated with either RA (11 SNPs) or CD (11 SNPs) by association testing in Dutch RA and CD cohorts and by meta-analyses including well-comparable data sets from two earlier GWAS on RA and CD.
RESULTS
In this study, we performed an association analysis with all SNPs showing replicated association to either RA or CD with a P-value cut-off of 5 Â 10
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. In total, 22 SNPs (11 primary CD-related and 11 primary RA-related SNPs) were genotyped or imputed in 1368 Dutch RA cases, 795 Dutch CD cases and 1683 controls. Since the distribution of males and females was substantially different in our cases and control cohort (frequency female in both case cohorts 60%,  whereas only 20% of controls were female, see Supplementary  Material, Table S2 ), we first compared the allele frequency of all the SNPs in males and females in our control cohort. None of the SNPs showed a significant difference (Supplementary  Material, Table S4 ), which we took as evidence for the comparability of the samples.
Replication of RA loci in Dutch RA cohort A replication of known RA variants in a Dutch RA cohort has not been performed previously. From a total of 11 RA loci, only the well-established risk variant in PTPN22 (rs2476601) showed a clear association with RA in our cohort (P ¼ 3.43 Â 10
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; OR ¼ 1.70 (95% confidence interval (CI): 1.46 -1.98)). Three other RA SNPs (rs3890745, rs4810485 and rs3218253 located in the MMEL1/ TNFRSF14, CD40 and the IL2RB gene regions, respectively) were nominally replicated in Dutch RA samples (P , 0.05). The remaining RA loci were not associated in our RA data set ( Table 1) .
Association of CD loci in Dutch CD cohort
All previously confirmed coeliac variants, except the LPP SNP rs1464510, showed association to CD in the Dutch cohort. This is not surprising since we used 508 of the 795 cases, and 833 of the 1683 controls as part of the multinational cohorts in our previous studies to establish the association of the CD loci (14, 20, 21) .
Cross-disease association study in the Dutch cohorts Three out of 11 primary CD-related SNPs were associated with RA in the Dutch cohort. The IL2/IL21 variant rs13151961 showed the strongest association to RA [P ¼ 0.0003; OR ¼ 0.78 (95% CI: 0.68 -0.89)]. This association was reported previously in a subset of our cohort (22) . We now confirmed the association of IL2/21 variants in an extended group of RA and CD cases. The other two variants, SH2B3 rs3184504 and LPP rs1464510, showed a moderate association with RA [P ¼ 0.024; OR ¼ 1.12 (95% CI: 1.02-1.25) and P ¼ 0.012; OR ¼ 1.14 (95% CI: 1.03 -1.26), respectively]. Opposing allelic association for RA and CD was observed for the LPP variant: the frequency of LPP rs1464510 Ã C allele was increased in RA compared with controls, whereas the rs1464510 Ã A allele was more frequent in CD patients than controls.
From the RA-specific variants, only rs3890745 from the MMEL1/TNFRSF14 locus showed a trend for association to CD [P ¼ 0.04, OR ¼ 0.87 (95% CI: 0.77-0.99)]. The rs10499194 variant in the TNFAIP3 locus, previously reported only in RA samples, also showed moderate association to CD [P ¼ 0.018; OR ¼ 0.84 (95% CI: 0.73-0.97)] ( Table 1) .
Stratification of RA samples for rheumatoid factor
As the association of several known RA genetic risk variants has been shown to be different in auto-antibody positive and negative cases (28), we performed a separate association analysis in rheumatoid factor (RF)-positive and RF-negative cases. We had information on RF status available for a subgroup of Dutch RA cases: 776 cases were RF positive and 204 RF negative. In the RF-positive group the SH2B3 variant rs3184504 showed stronger association compared to the total RA cohort (P ¼ 0.0055, OR ¼ 1.19 (95% CI: 1.05 -1.34) ( Table 2 ). We did not perform stratification on anti-CCP auto-antibodies, as the anti-CCP status was only available for a minority of cases.
Meta-analysis
To increase the power of the study, we combined our data with those of a GWAS in RA and CD patients from the UK into a meta-analysis. The UK cohorts included 1860 cases and 2938 controls from the WTCCC study on RA, and 767 CD cases and 1422 controls from a UK GWAS in CD (13, 21) . In the meta-analysis, four risk loci showed association to both RA and CD with P , 0.01, including the genes IL2/IL21, LPP, TNFAIP3 and SH2B3 (Table 3) . Association with the LPP locus in CD and RA was observed for opposing alleles.
A trend for association with SNPs in MMEL1-TNFRSF14 and PRKCQ was observed for both diseases (P , 0.05) ( Table 3 ). An overview of the common and separate associations of the tested genes with RA and CD is shown in Figure 1 .
DISCUSSION
In this study, we (i) performed the replication of known RA associated loci in our Dutch cohort of RA cases and controls;
(ii) performed the cross-study of RA and CD associated variants in Dutch RA and CD cohorts and (iii) combined our results in a meta-analysis with the UK GWAS in RA and CD (13, 21) . We were able to replicate 4 out of 11 RA loci in our Dutch RA cohort, and identified 6 loci which showed shared association to CD and RA in the meta-analysis. Strikingly, most of the previously established RA SNPs were not replicated. There are several reasons for this observation. First, the endophenotyping difference might be the major reason for non-replication: several of the RA loci were established mainly in subgroups of ACPA-positive RA patients. Differential association in auto-antibody positive and negative subgroups of RA has been reported previously (28) . We could not stratify for ACPA in our cohort due to lack of ACPA status for most patients. However, when stratified for RF, we were able to observe a stronger effect for the variant in the SH2B3 gene. Secondly, population heterogeneity might be another explanation for lack of association with the initial reported variants. To control for the heterogeneity of the association test, we included the Breslow -Day test in our analysis. Two of the SNPs (rs4750316 and rs1678542, the PFKFB3/PRKCQ and KIF5A locus, respectively) showed significant results for this test, indicating the presence of heterogeneity between the two populations. Further replication in other populations is essential for establishing the true risk effect of these genes. Since we only tested a single marker (the most associated one for each locus), we may have missed the association due to low/other linkage disequilibrium (LD) between the established 'tagging' SNP and the true causal variant in the Dutch population. Finally, the relative risk of associated regions in the initial studies was rather low (OR between 0.75 and 1.32 for most SNPs). Moreover, similar to the single gene association studies, the effect of some of the established loci might be overestimated and our Depending on the SNP, the power of our study ranged from 0.2-1 in the Dutch cohorts and increased in the meta-analysis to a range of 0.34 -1 (Supplementary Material, Table S5 ).
The power was at 80% or above for 16 out of 22 SNPs for the RA NL-UK combined analysis and above 80% for 8 out of 22 SNPs for the CD NL-UK analysis. All these factors, or combinations of them, might explain the negative results for most of the genes we tested. Further replication studies in various populations and endophenotypes would shed light on the effect and heterogeneity of associated loci in RA.
In the combined Dutch and UK data sets, we observed a convincing shared association of four genes to RA and CD (P , 0.01 in both diseases), and suggestive association of two more loci (P , 0.05 in both diseases). Two of the shared loci, IL2/IL21 and TNFAIP3, are already known to be involved in both diseases and were confirmed in our study. The meta-analysis for rs42041 was not done due to poor imputation of this SNP in the UK and Dutch GWAS data sets. Figure 1 . Association of 20 investigated loci to CD and RA. From the IL12A-SHIP locus and OLIG3-TNFAIP3 locus, one of two SNPs (the most associated one, rs17810546 and rs2327832, respectively) are included in the figure. The SNP rs42041 was excluded from the meta-analysis due to poor imputation quality. Blue dots and corresponding line-OR and 95% CI for RA. Red dots and lines-OR and 95% CI for CD. OR was calculated for the minor allele of associated SNP. (32) . This points to a general role for these genes in the development of autoimmunity. The association of IL2-IL21 locus to several immune-related diseases is especially interesting, although strong LD in this locus makes it difficult to locate the true associated gene. Both IL2 and IL21 are important in Tregulatory and Th17 cells, respectively. Both CD and RA show high levels of Th17 in affected tissues (33, 34) . Interestingly, IL21 is produced by Th17 cells and is important for maintaining Th17 cells (35) . High levels of IL21 have been found in the intestine of patients with CD (21), whereas IL21 receptor is overexpressed in synovial tissues of RA patients (36) . Blockading the IL21/IL21R pathway ameliorates disease in a murine model of RA (37) .
The association of SH2B3 with both RA and CD has not been reported previously. The SH2B3 rs3184504 variant is a non-synonymous SNP R262W located in exon 3 of the gene, and has previously been associated with CD, type 1 diabetes and myocardial infarction (14, 24, 38) . It encodes the T-cell adapter protein LNK, which regulates T-cell receptor-, growth factor-and cytokine receptor-mediated signalling, and is therefore an attractive candidate gene for shared autoimmune susceptibility (39) .
Another shared gene identified in this study, LPP (LIM domain containing preferred translocation partner in lipoma), is involved in cell adhesion, cytoskeletal remodelling and maintaining cell shape and motility (40, 41) . Chromosomal aberrations including the LPP region have been observed in leukaemia, indicating a potential role for this chromosomal region in regulating the immune system (42) . The exact function of LPP in autoimmunity has not yet been defined. Interestingly, in our study, LPP shows a differential association for RA and CD. The effect of LPP rs1464510 Ã A allele confers protection in RA, and susceptibility in CD. The reason for the opposing allelic associations could be the presence of distinct RA-and CD-causing variants, located on different haplotypes and tagged by the opposite alleles of the same SNP. Another possibility is that the same variant confers truly susceptibility to one disease and protection from another, similar to the PTPN22 functional variant Arg620Trp, which confers susceptibility to several autoimmune diseases, but protection from Crohn's disease (43, 44) . Sequencing of the whole associated block in both diseases is required to define the RA and CD causal variants and explain the exact nature of this observation. Association of opposite alleles to different autoimmunities has been also observed for IL18RAP and TAGAP variants in CD and type 1 diabetes (45) .
Two loci showed moderate association to both diseasesthe PFKFB3/PRKCQ and MMEL1-TNFRSF14 (P , 0.05). The PFKFB3/PRKCQ variant was originally reported in a meta-analysis including RA patients (17) . In addition, the same locus has recently been associated with type 1 diabetes in a meta-analysis (46) . Thus, our findings, although only moderately significant, provide additional support for this locus being a shared autoimmune gene. PRKCQ is involved in regulating and controlling T-cell-mediated signalling and is therefore a plausible candidate for autoimmune traits (47) The MMEL1/TNFRSF14 locus includes the TNFRSF14 (HVEM, herpes virus entry mediator) gene, which functions as a co-stimulatory molecule during T-cell activation (48) , and enhances the bactericidal activities of human monocytes and neutrophils (49) . In antiviral responses, TNFRSF14 is involved in NF-kB activation.
Overall, from six shared CD-RA loci, five contain genes directly involved in immune function. Association to the SH2B3, PRKCQ, IL2/21 and TNFRSF14 genes points to the role of T-cell-mediated signalling, whereas both the TNFAIP3 and TNFRSF14 genes are linked to NF-kb signalling, innate immunity and the response to pathogens. The association of innate molecules to RA and CD may now explain the link of mucosal immunity state and infections in predisposition to both diseases (50 -52) .
Our study extends the knowledge on genes that are shared between RA and CD. Most of the shared genes fit with the current hypotheses on the pathogenesis of these diseases, involving both innate and adaptive immunity. Several of the shared genes also contribute to the susceptibility to additional autoimmune diseases. Creating genetic profiles for autoimmunity may help understand the basic mechanisms of pathogenesis and predict common immune-related risk factors/ phenotypes. Furthermore, it will open up possibilities for the development of new drug targets for a better treatment of autoimmune diseases.
MATERIALS AND METHODS

Study population
Rheumatoid arthritis cohorts. We combined two independent Dutch RA inception cohorts: from Nijmegen (n ¼ 960) and Groningen (n ¼ 408). Both cohorts have been described elsewhere (22, 53, 54) . All patients were diagnosed according to the American College of Rheumatology (ACR) criteria for RA (55) . Due to the lack of whole genome data, we ascertained subjects were of Dutch descent based on their surname.
Coeliac disease cohorts. Our study analysed 795 unrelated Dutch individuals with CD. All affected individuals were diagnosed according to the revised ESPGAN criteria (56) . The cohort encompassed individuals that showed a Marsh II or Marsh III lesion in the initial diagnostic small-bowel biopsy specimens upon re-evaluation by one of two experienced pathologists, or presented with dermatitis herpetiformis and were HLA-DQ2 positive.
Control cohort. The control cohort comprised unrelated blood bank donors (n ¼ 833) and NELSON controls (n ¼ 850). The blood bank control cohort was described earlier (14, 20) . Other controls were included from the NELSON project-an ongoing population-based, randomized multi-centre lung cancer screening trial, studying male smokers (57) . These controls were collected from the north and centre of the Netherlands (Groningen, Utrecht and Drenthe, The Netherlands). All the control subjects were heavy smokers or ex-smokers (a minimum of 16 cigarettes/day for 25 years or 11 cigarettes/day The current study was approved by the local ethics committees and all the patients and controls gave their written informed consent. Information on male/female ratio of the cohorts is shown in Supplementary Material, Table S2 .
SNP selection and genotyping
We selected SNPs with confirmed association to either RA or CD with P , 5 Â 10 206 from existing literature. Information on the original studies and the associated SNPs is given in Supplementary Material, Table S1 . In total, we tested 22 SNPs from 20 loci, 11 known for association to CD and 11 primarily associated to RA, with two of the genes known to be associated to diseases.
Genotyping of Dutch RA samples. All 22 SNPs were genotyped in the Dutch RA cohort using TaqMan probes and primers developed by Applied Biosystems, on an ABI 7900HT system (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Genotyping was performed following the manufacturer's specifications. DNA samples were processed in 384-well plates, each plate contained 8 negative controls and 5 duplicated samples. All duplicates showed consistent results for all SNPs.
Genotyping of Dutch CD samples and controls. Of the 22 SNPs, 15 were present on the Illumina HAP550 platform. The genotyping data of CD cases and controls for these 15 SNPs were extracted from an ongoing GWAS in the Dutch population, performed on the Human670-QuadCustom Illumina BeadChips, which contains the HumanHap550 SNP set (manuscript in preparation). The remaining seven SNPs were not present on the genotyping platforms. In these cases, a 4 MB window around the SNP of interest was imputed using Plink v1.05 (http://pngu.mgh.harvard.edu/purcell/plink/) and the phase 2, HapMap CEU samples, release 23a, as the imputation reference panel (58) . We included the imputed genotypes only if the imputation quality was above 0.8 (Supplementary Material, Table S3 ). The SNP rs42041 showed deviation from Hardy-Weinberg equilibrium (HWE) in the Dutch GWAS imputed data set, so this SNP was genotyped by TaqMan in Dutch CD cases and the blood bank control group (n ¼ 833). NELSON controls (n ¼ 850) were not genotyped for the rs42041. For CD, genotyping results for 15 SNPs were extracted from the UK GWAS study (21) . The non-genotyped SNPs were imputed in the UK cases and controls (imputation quality (info) .0.8, except for the SNP rs42041, which could not be imputed with sufficient quality and was therefore excluded from the meta-analysis (Supplementary Material, Table S3 ).
The genotyping method and imputation quality in each cohort is presented in Supplementary Material, Table S3A -C. The frequency of missing genotypes was below 5% for all the SNPs in all the genotyped cohorts.
Population substructure analysis
Multidimensional scaling analysis (implemented in Plink) was applied to all the samples for which genome-wide genotype data were available. The values of the first five components were further plotted against each other. We detected outlying samples only for the first three components. Samples exceeding two standard deviations from the mean for the first three components were excluded, ensuring that only the most homogeneous samples were included in our final analysis and that there was no population stratification.
As a part of the ongoing GWAS in celiac disease, we applied a multidimensional scaling (MDS) analysis to assess whether there was a large population substructure between the UK and Dutch cohorts. Both cohorts created tight clusters and, as expected, the two first components could distinguish between the two populations. However, over 40% of the samples shared a common part in the plot. Both cohorts were also merged with the HapMap2 data and the MDS analysis was repeated. Both cohorts mapped perfectly to the CEU population, any outlying samples that mapped outside the cluster were excluded from further analysis.
Statistical analysis
We calculated HWE for all the genotyped SNPs by comparing the expected and observed genotypes in a 2Â3 chi-square table. None of the markers deviated significantly from HWE in cases or controls (P . 0.01) in any of the populations. Association analysis was performed using chi-square statistics with two-tailed P-values (implemented in Plink v1.05) (58) . In the meta-analysis, we combined the information on allele counts for the Dutch and UK cohorts separately for CD and RA, in the Mantel -Haenszel chi-square association test with two clusters. P-values, odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated using Plink v1.05.
To estimate the heterogeneity of the association tests between the populations, we performed the Breslow -Day test. All except two SNPs described in this study were negative for this test. Rs4750316 and rs1678542 showed significant results for the Breslow -Day test in the RA cohort and we therefore applied the random-effect model for nonheterogeneous studies (the DerSimonian -Laird method implemented in the rmeta package for R; www.r-project.org).
Power calculation
We calculated the power of our sample size to detect significant associations using the Genetic Power Calculator (http://pngu. 
